COST-EFFECTIVENESS ANALYSIS OF ADDITION OF BEVACIZUMAB TO A STANDARD CHEMOTHERAPY DOUBLET (PEMETREXED + CISPLATIN) IN PATIENTS WITH MALIGNANT PLEURAL MESOTHELIOMA
Author(s)
Malacan J, Carlson JJ
University of Washington, Seattle, WA, USA
OBJECTIVES: A recent Phase III trial, the MAPS (Mesothelioma Avastin Cisplatin Pemetrexed Study), investigated the addition of bevacizumab to cisplatin plus pemetrexed in malignant pleural mesothelioma (MPM) patients. The trial results indicate that patients taking bevacizumab had improved progression free survival (PFS) and overall survival (OS) compared with the bi-therapy group. Our objective was to evaluate the cost-effectiveness of adding bevacizumab to cisplatin and pemetrexed in a US setting, from a payer perspective. METHODS: A Markov model with three health states - pre-progression, progression and death – was developed to estimate the cost-utility of bevacizumab plus pemetrexed plus cisplatin, versus pemetrexed plus cisplatin. The model used monthly cycles and a 3% discount rate. The data on PFS and OS were derived from the MAPS study. Utility data were derived from the literature and are consistent with other MPM models. Costs included treatment, administration, adverse events, and supportive care and were calculated based on average sales price, diagnosis-related group payments, current procedural terminology codes and publications in the literature. Sensitivity analyses were run to evaluate the impact of parameter uncertainty. RESULTS: Compared to the doublet therapy alone, bevacizumab plus pemetrexed plus cisplatin resulted in 2.28 more life years (LYs), 2.02 more quality-adjusted life years (QALYs), and an additional cost of $147,713 per individual. This results in an Incremental Cost Effectiveness Ratio of $ 64,700/LY and $ 73,081/QALY. A one-way sensitivity analysis showed that the inputs with the most impact on the results were patient’s utility scores and bevacizumab drug cost. CONCLUSIONS: The addition of bevacizumab to the current standard of care may be considered cost-effective from an US payer perspective according to commonly used willingness-to-pay thresholds. However further analysis could be performed with the release of more data from the MAPS clinical trial.
Conference/Value in Health Info
2016-05, ISPOR 2016, Washington DC, USA
Value in Health, Vol. 19, No. 3 (May 2016)
Code
PCN111
Topic
Economic Evaluation
Topic Subcategory
Cost-comparison, Effectiveness, Utility, Benefit Analysis
Disease
Oncology, Rare and Orphan Diseases